Wall Street brokerages forecast that Aspen Aerogels, Inc. (NYSE:ASPN) will post earnings per share of ($0.26) for the current quarter, Zacks reports. Six analysts have issued estimates for Aspen Aerogels’ earnings, with estimates ranging from ($0.27) to ($0.24). Aspen Aerogels posted earnings of ($0.25) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 4%. The firm is expected to report its next quarterly earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Aspen Aerogels will report full year earnings of ($0.98) per share for the current fiscal year, with EPS estimates ranging from ($1.02) to ($0.95). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.82) to ($0.57). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aspen Aerogels.
Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Wednesday, July 28th. The construction company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.04. The company had revenue of $31.67 million during the quarter, compared to the consensus estimate of $25.35 million. Aspen Aerogels had a negative net margin of 24.17% and a negative return on equity of 30.20%.
In other news, VP Kelley Conte sold 36,717 shares of Aspen Aerogels stock in a transaction dated Wednesday, August 25th. The shares were sold at an average price of $42.75, for a total transaction of $1,569,651.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 13.30% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of ASPN. Parametric Portfolio Associates LLC bought a new position in shares of Aspen Aerogels in the second quarter worth approximately $209,000. Bradley Foster & Sargent Inc. CT purchased a new stake in Aspen Aerogels during the second quarter valued at approximately $461,000. Invesco Ltd. purchased a new stake in Aspen Aerogels during the second quarter valued at approximately $2,584,000. Metropolitan Life Insurance Co NY increased its holdings in Aspen Aerogels by 102,050.0% during the second quarter. Metropolitan Life Insurance Co NY now owns 6,129 shares of the construction company’s stock valued at $183,000 after buying an additional 6,123 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in Aspen Aerogels by 406.1% during the second quarter. Millennium Management LLC now owns 442,761 shares of the construction company’s stock valued at $13,247,000 after buying an additional 355,277 shares during the last quarter. 86.38% of the stock is currently owned by institutional investors and hedge funds.
NYSE:ASPN traded down $0.61 during trading hours on Thursday, hitting $45.98. The stock had a trading volume of 1,747 shares, compared to its average volume of 254,044. The company has a 50 day simple moving average of $40.66 and a two-hundred day simple moving average of $28.79. Aspen Aerogels has a one year low of $10.17 and a one year high of $47.29. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -50.10 and a beta of 1.50.
About Aspen Aerogels
Aspen Aerogels, Inc engages in designing, developing, and manufacturing aerogel insulation used primarily in the energy infrastructure and building materials markets. Its products include Cryogel, Pyrogel, and Spaceloft. The company was founded by Hamed S. Borhanian, Patrick J. Piper, and Kang P. Lee on May 4, 2001 and is headquartered in Northborough, MA.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aspen Aerogels Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels and related companies with MarketBeat.com's FREE daily email newsletter.